Bayer to invest $2.2bn in New Albany, Ohio pharmaceutical manufacturing site
- Bayer will invest $2.2 billion to build a new modular pharmaceutical manufacturing campus in New Albany, Ohio.
- The company expects about 600 permanent high-value jobs and roughly 1,500 construction jobs.
- First module for drug substance manufacturing targeted to be operational in 2031, with a drug product module planned for 2034.
- The campus will initially support oncology, cardiovascular and renal-care products and incorporate advanced digital and automation technologies.
Project and investment
Bayer announced a $2.2 billion investment to build a new pharmaceutical manufacturing campus in New Albany, Ohio, expanding its U.S. pharma R&D and production footprint that follows more than $7 billion in U.S. pharma R&D and manufacturing spending over the past five years.
Site design and capabilities
The flexible, modular campus is planned to combine drug substance and drug product manufacturing, leverage advanced digital and automation technologies, and initially support oncology, cardiovascular and renal-care products.
Timeline and capacity
The first module, dedicated to drug substance manufacturing, is expected to become operational in 2031, with a second module for drug product manufacturing planned for 2034.
Jobs, network and strategy
Bayer expects the site to create about 600 high-value permanent jobs and roughly 1,500 construction jobs. The facility will complement Bayer’s existing U.S. locations and form part of a new U.S.-based collaboration ecosystem connecting academic innovation with advanced manufacturing expertise to strengthen supply resilience and patient access.
Source: Bayer